Search

Author/Creator Jones, Surai

1. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Issue 5 (May 2019)

Authors:
Morschhauser, Franck; Flinn, Ian W; Advani, Ranjana; Sehn, Laurie H; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W; Salles, Gilles; Tilly, Hervé; Chen, Andy I; Assouline, Sarit; Cheson, Bruce D; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan;...
Journal:
Lancet
Issue:
Volume 6:Issue 5(2019)
Page Start:
e254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Issue 6 (June 2015)

Authors:
Palanca-Wessels, Maria Corinna A; Czuczman, Myron; Salles, Gilles; Assouline, Sarit; Sehn, Laurie H; Flinn, Ian; Patel, Manish R; Sangha, Randeep; Hagenbeek, Anton; Advani, Ranjana; Tilly, Herve; Casasnovas, Olivier; Press, Oliver W; Yalamanchili, Sreeni; Kahn, Robert; Dere, Randall C; Lu, Dan; J...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 6(2015:Jun.)
Page Start:
704
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search